About allogene therapeutics inc. - ALLO
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
ALLO At a Glance
Allogene Therapeutics, Inc.
210 East Grand Avenue
South San Francisco, California 94080-4811
| Phone | 1-650-457-2700 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -190,886,000.00 | |
| Sector | Health Technology | Employees | 152 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ALLO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.074 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.695 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.615 |
ALLO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,255,828.947 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ALLO Liquidity
| Current Ratio | 7.927 |
| Quick Ratio | 7.927 |
| Cash Ratio | 7.695 |
ALLO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -39.578 |
| Return on Equity | -53.416 |
| Return on Total Capital | -50.795 |
| Return on Invested Capital | -43.73 |
ALLO Capital Structure
| Total Debt to Total Equity | 28.458 |
| Total Debt to Total Capital | 22.154 |
| Total Debt to Total Assets | 20.017 |
| Long-Term Debt to Equity | 25.653 |
| Long-Term Debt to Total Capital | 19.97 |